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ABSTRACT
MicroRNAs are critical regulators of gene networks in normal and abnormal 
biological processes. Focusing on invasive ductal breast cancer (IDC), we have found 
dysregulated expression in tumor samples of several microRNAs, including the miR-
200 family, along progression from primary tumors to distant metastases, further 
reflected in higher blood levels of miR-200b and miR-7 in IDC patients with regional 
or distant metastases relative to patients with primary node-negative tumors. Forced 
expression of miR-200s in MCF10CA1h mammary cells induced an enhanced epithelial 
program, aldehyde dehydrogenase (ALDH) activity, mammosphere growth and ability 
to form branched tubuloalveolar structures while promoting orthotopic tumor growth 
and lung colonization in vivo. MiR-200s also induced the constitutive activation of the 
PI3K-Akt signaling through downregulation of PTEN, and the enhanced mammosphere 
growth and ALDH activity induced in MCF10CA1h cells by miR-200s required the 
                                                  Priority Research Paper
Oncotarget83385www.impactjournals.com/oncotarget
INTRODUCTION
The acquisition of metastatic properties by cancer 
cells requires both the occurrence of genetic events that 
confer a minority of neoplastic cells with inherent self-
renewal properties that no longer rely on environmental 
cues specific to the tissue of origin and also the epigenetic 
remodeling of selected properties that allow the cells to 
overcome environmental hurdles to metastasis [1]. As 
opposed to mutations, epigenetic processes are reversible 
and are used by cancer cells as a survival strategy that 
allows them to switch phenotypes in order to optimize 
adaptation to potentially hostile environmental conditions 
[1].
MicroRNAs are epigenetic regulators that modulate 
gene networks that determine the balance between cell 
invasion vs. cohesion, proliferation vs. quiescence, and 
senescence vs. cell death [2, 3]. Many microRNAs display 
dysregulated expression in neoplastic states and either 
confer or repress the metastatic properties to tumor cells 
in experimental models [4]. Herein, we have assessed the 
role of microRNAs in regulating the ability of invasive 
breast ductal carcinoma (IDC) cells to metastasize to 
local lymph nodes as a surrogate marker of metastatic 
potential. We report that the miR-200 family members are 
significantly upregulated in lymph node (LN) metastases 
and, by using the MCF10CA1 mammary cell model, that 
miR-200s induce features of mammary luminal progenitor 
cells, which may explain the association of enhanced self-
renewal, tumorigenesis and metastatic potentials with high 
levels of expression of miR-200s.
RESULTS
Identification of sets of microRNAs dysregulated 
along IDC metastatic progression
Focusing on lymph node spread as a readout 
for the metastatic potential of cancer cells, we sought 
to identify microRNAs (miRNAs) with dysregulated 
expression in the course of IDC metastatic progression. 
For this, a miRNA microarray expression screening was 
performed using tissue samples from 8 ductal carcinomas 
in situ (DCIS), 20 primary IDC without LN involvement 
(PNM), 20 primary IDC with regional LN involvement 
(PM), 20 LN metastases matched to the node-positive 
primary tumors (LNM) and 20 distant metastases (DM) 
(Supplementary Table 1) and a pool of 10 normal breast 
epithelial tissues (N). This analysis yielded miRNAs 
that were significantly upregulated in the transition from 
normal breast tissues to PM, including miR200a, miR-
200b and miR-429 (Figure 1A). Another set of miRNAs, 
including miR-181a, miR-181b, miR- 210 or miR-7 was 
upregulated in DM relative to primary tumors (Figure 1A). 
qPCR confirmed that miR-200b, miR-7 and miR-210 are 
significantly upregulated from PNM to PM, while miR-
7, miR-210, miR-181a and miR-181b were up-regulated 
in DM relative to node-negative tumors (Figure 1B). 
Furthermore, higher levels of miR-200a, miR-200b and 
miR-429 were expressed in a majority of LNM samples 
compared to their matched primary tumors (Figure 2A). 
Consistently, staining of these samples for E-cadherin, a 
hallmark of the epithelial reprogramming driven by miR-
200s, revealed a generally stronger staining intensity in 
LNM cancer cells when compared to matched primary 
tumors (Figure 2B).
Although the primary mode of breast cancer 
dissemination is lymphogenous [5], if LN metastasis 
reflects a general propensity of breast cancer cells for 
metastatic spread, similar changes might be detected in 
the blood as circulating miRNAs. Because the tissue levels 
of miR-200b, miR-200c, miR-7, miR-10b, miR-148, miR-
101, miR-30a*, miR-181a, miR-181b and miR-210 were 
significantly dysregulated during metastatic progression, 
we determined their levels in blood samples prospectively 
collected from 78 patients with a diagnosis of IDC 
(Supplementary Table 2). Patients with node-positive 
tumors at the time of diagnosis displayed higher miR-200b 
and miR-7 blood levels than patients with node-negative 
tumors (Figure 2C). Differences were also significant 
when comparing patients with distant metastases to those 
bearing only primary tumors (Figure 2C). The blood levels 
of miR-210 were significantly lower in patients with 
distant metastasis relative to those with node-negative 
primary tumors (Figure 2C). The remainder of the 
microRNAs analyzed did not show significant differences 
in their blood levels between any of the patient groups 
studied (not shown). The observed concordance between 
increased levels of miR-200b and miR-7 during metastatic 
progression in both tumor tissues and blood argue in favor 
of a carcinomatous origin of the circulating miRNAs. 
activation of this signaling pathway. Interestingly, the morphology of tumors formed in 
vivo by cells expressing miR-200s was reminiscent of metaplastic breast cancer (MBC). 
Indeed, the epithelial components of MBC samples expressed significantly higher levels of 
miR-200s than their mesenchymal components and displayed a marker profile compatible 
with luminal progenitor cells. We propose that microRNAs of the miR-200 family promote 
traits of highly proliferative breast luminal progenitor cells, thereby exacerbating the 
growth and metastatic properties of transformed mammary epithelial cells.
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miR-200s promote luminal progenitor properties 
in tandem with tumorigenic and metastatic 
growth of MCF10CA1h cells
The above results suggest that metastatic breast 
cancer cells express increased miR-200 levels as 
compared to primary tumor cells and thus are expected 
to display an enhanced epithelial phenotype. Although 
several studies have found an association between low 
miR200 levels with invasive cancers and poor prognosis, 
concluding that constitutive expression of miR-200s 
Figure 1: MicroRNAs dysregulated along malignant invasive ductal carcinoma (IDC) progression. A. Microarray analysis 
of relative expression levels of miRNAs differentially expressed between samples of normal breast epithelium (N), ductal carcinoma in situ 
(DCIS), primary IDC with no regional lymph node involvement or distant metastasis (PNM), primary IDC with lymph node involvement 
(PM), matched lymph node metastases (LNM) or distant metastases (DM). The heatmap was generated after probe normalization and 
selection of differentially expressed miRNAs. B. Quantification by qPCR of levels of selected miRNAs along metastatic progression of 
IDC. Reference probe-normalized values (n- ΔCt) are shown relative to the median of values for normal breast epithelial tissues (N).
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Figure 2: Upregulation of microRNA 200s in association with lymph node involvement in IDC. A. miR-200s are frequently 
expressed at higher levels in lymph node metastases than matched primary tumors. Shown are ratios (fold-change) of qPCR values (n- ΔCt) 
for the indicated miRNAs in lymph node metastases (LNM) and their matched primary tumor (PM). B. Semiquantification of E-cadherin 
immunostaining of primary (PM) and matched metastatic (lymph node, LNM) ductal breast cancer samples. C. Blood levels of miR-
200b and miR-7 tend to be higher, and levels of miR-210 lower, along metastatic progression in breast cancer patients. Reference probe-
normalized values (n- ΔCt) are shown relative to the median of values for blood samples from patients with non-metastatic node-negative 
IDC (PNM µ
1/2
).
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Figure 3: Phenotypic effects of miR-200s expression in MCF10CA1h cells. A. Cell lines with stronger metastatic potential 
express higher levels of miR-200b. The MDA-MB-468 (highly metastatic) breast cancer cell line was compared to MCF7 cells (poorly 
metastatic), the MDA-MB-231-derived SCP2 clonal cell line (highly metastatic) to the SCP6 clone (significantly less metastatic) and 
the MCF10 breast epithelial-derived MCF10CA1a subpopulation (moderately metastatic) to the MCF10CA1h subpopulation (non-
metastatic). Shown are ratios (fold-change) for the compared cell lines of reference miR-normalized qPCR values (n- ΔCt) for the indicated 
miRs. B. MiR-200s induce a mesenchymal-to-epithelial transition (MET) in MCF10CA1h cells, with upregulation of epithelial markers 
(CDH1, DSP and EPCAM), downregulation of mesenchymal markers (ZEB1, ZEB2, TWIST1, TWIST2, FN1) as well as upregulation 
of basal (KRT5, KRT14) and luminal (KRT8, KRT18) keratins. Heatmap of relative mRNA levels of epithelial & mesenchymal markers 
in MCF10CA1h.C2 vs MCF10CA1h.Control cells. Values for genes with significant differential expression between the two cell lines, 
determined by statistical analysis of microarrays (SAM) were submitted to hierarchical clustering and plotted in a heatmap. Shown on 
the right are the symbols of selected genes relevant in epithelial and mesenchymal gene programs. C. MET and basal marker induction in 
MCF10CA1h cells determined by qPCR (cluster 1 miR-200s) and Western blotting (cluster 1 - C1 - and cluster 2 - C2 - miR200s). MiR-
200 induce a mesenchymal-to-epithelial transition (MET) in MCF10CA1h cells, with upregulation of CDH1 and EPCAM, downregulation 
of mesenchymal markers ZEB1, ZEB2, FN1 and ACTA2, as well as upregulation of basal (KRT5, KRT14) and luminal (KRT8, KRT18) 
keratins and downregulation of SOX2 (but not POU5F1, KLF4, MYC or BMI1). Shown are ratios (fold-change) for MCF10CA1h.C1 vs. 
MCF10CA1h. Control of RP18S-normalized qPCR values (n- ΔCp) for the indicated mRNAs D. Highly divergent morphologies of control 
and miR-200 (C2) - expressing MCF10CA1h cells grown as adherent cells on a plastic surface (top) or in 3-dimensional collagen I matrices 
(bottom). 
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suppresses invasiveness and metastatic potential in 
xenotransplanation models [6, 7], more recent studies have 
reported that high-burden metastatic breast cancer cells 
express an epithelial gene program [8] and that miR-200s 
can play pro-metastatic roles [9-12]. To address this issue, 
we quantified the expression levels of miR200b in cancer 
cell models displaying differential metastatic potentials. 
Remarkably, two clonal lines derived from MD-MBA-231 
basal-like cancer cells [13] presented a striking differential 
expression of miR-200b, with the highly metastatic SCP2 
cells expressing 60-fold higher levels of miR-200b relative 
to poorly metastatic SCP6 cells (Figure 3A). Additionally, 
two subpopulations derived from the non-cancerous 
MCF10 cell line [14, 15], the moderately metastatic 
MCF10CA1a and the non-metastatic MCF10CA1h cells, 
also presented an unambiguous differential expression 
profile of miR200s, with MCF10CA1a cells expressing 
miR200b levels up to 3 orders of magnitude higher than 
Figure 4: MiR-200s promote the mammosphere growth and ALDH activity of MCFCA1h cells. A. miR-200-Cluster1 
(C1; left) and miR-200-Cluster 2 (C2; right) microRNAs potentiate the mammosphere growth of MCF10CA1h cells. Cells (6 x 103/
well) were seeded in low-attachment plates and allowed to grow for 7 days (primary mammospheres, M1), disgregated and reseeded for 
secondary mammosphere formation (M2). Quantification was done after MTT staining and image analysis (n = 3). B. miR-200-C1 (left) 
and miR-200-C2 (right) strongly induce aldehyde dehydrogenase activity in MCF10CA1h cells. Cells were trypsinized and ALDH activity 
determined with the Aldefluor assay and flow cytometry. Windows for baseline fluorescence levels were established for cells incubated 
with the Aldefluor reagent and the ALDH inhibitor diethylaminobenzaldehyde (DEAB). C. miR-200-C1 (left) and miR-200-C2 (right) 
upregulate cell-surface CD24 in MCF10CA1h cells. Cells in suspension were incubated with Alexa Fluor 647-labeled anti-CD44 and Alexa 
Fluor-488-labeled anti-CD24 and analyzed by flow cytometry. 
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those of MCF10CA1h cells (Figure 3A).
These MCF10 subpopulations are transformed 
variants of cells derived from non-tumoral mammary 
epithelial cells, with the MCF10CA1h subpopulation 
displaying a mesenchymal-like morphology and low 
anchorage-independent mammosphere growth potential 
relative to the more epithelial MCF10CA1a subpopulation 
[15]. We exploited these distinctive growth features to test 
the phenotypic consequences of the ectopic expression of 
miR-200s. Transduction of MCF10CA1h cells with miR-
200 cluster 1 (C1; miR-200a, miR-200b, miR-429) or 
cluster 2 (C2; mir-200c, miR-141) induced an epithelial 
gene program with a strong upregulation of the epithelial 
genes, E-cadherin, EpCAM, and desmoplakin, together 
with a downregulation of the mesenchymal markers 
fibronectin, smooth muscle cell actin, TWIST1/2 or 
ZEB1/2 (Figure 3B-3C), accompanied with characteristic 
epithelial morphologies either grown on plastic or 
embedded in 3-D collagen I gels (Figure 3D). This gain in 
epithelial gene program and phenotype was accompanied 
with an inhibition of the capacity of miR-200-expressing 
MCF10CA1h cells to migrate in wound healing and 
invasiveness assays (Supplementary Figures S1 and S2).
Importantly, transduction of miR-200s strongly 
enhanced the capacity of MCF10CA1h cells to form 
primary and secondary mammospheres (Figure 4A). 
This was accompanied with a striking 10-fold induction 
of aldehyde dehydrogenase (ALDH) activity (Figure 4B 
and Supplementary Figure 3). Further, miR-200s elicited 
a shift of MCF10CA1h cells from a CD44highCD24low to 
a CD44highCD24high cell surface haplotype (Figure 4C). 
While mammary epithelial stem cells are preferentially 
enriched in the CD44highCD24low population [16], 
the CD44highCD24high population encompasses more 
committed cell populations, including highly proliferating 
luminal progenitor cells and differentiated luminal cells 
[17], that likewise express high levels of ALDH activity 
[18, 19]. The upregulation of ALDH activity in miR-
200-expressing MCF10CA1h cells was not accompanied 
with unamibugously enhanced resistance to drugs such as 
cis-Pt, etoposide, olaparib or docetaxel (Supplementary 
Figure 4). Taken together, these features are consistent 
with a miR200-mediated induction of a progenitor luminal 
state in mammary cells [17, 18, 20, 21].
To identify miR-200 targets that potentially control 
mammary cell fate determination, we quantified the 
expression levels in MCF10A1h cells a series of predicted 
miR-200 targets (http://www.microrna.org/microrna/
home.do, http://www.targetscan.org/). Transcript levels 
for ZEB1, ZEB2, RECK, QKI, TSC1, SYNJ1 and 
PTEN were strongly downregulated upon expression 
of miR-200s (Figure 5A). Consistent with the observed 
downregulation of the PI3K-Akt negative regulator 
PTEN, an enhanced steady-state phoshporylation of Akt in 
MCF10CA1h.C1, MCF10CA1h.C2 or MCF10CA1h.200b 
cells relative to control cells was observed (Figure 5B). 
Furthermore, the gain in mammosphere formation 
conferred by miR-200s was completely abolished by 
the PI3K inhibitor, LY294002 or the mTOR inhibitor, 
rapamycin (Figure 5C), supporting a model wherein the 
miR-200-dependent activation of these signaling pathways 
promotes mammosphere formation. While novel miR-
200a and miR-200b target status was demonstrated for the 
mTOR negative regulator, TSC1, PTEN was not directly 
targeted (Figure 5D), suggesting an indirect mechanism 
of downregulation by miR-200s [22]. In this regard, 
overexpression of miR-200 cluster 2 in MCF10CA1h cells 
caused an upregulation of miR-205 (Figure 5E), known to 
directly target PTEN, suggesting a mechanism whereby 
miR-200’s induce the expression of miR-205, which in 
turn targets and downregulates PTEN. In support for a 
role of PTEN downregulation in the phenotype induced by 
mir-200, direct knockdown of PTEN in MCF10CA1h cells 
significantly enhanced mammosphere growth (Figure 5F). 
However, it failed to upregulate ALDH activity (Figure 
5G) or the number of CD24pos cells (Figure 5H). On the 
other hand, knockdown of ZEB2 in MCF10CA1h cells 
(Supplementary Figure S5) caused both a strong increase 
in mammosphere growth (Figure 6A) and ALDH activity 
(Figure 6B). Surprisingly, ZEB2 knockdown, despite 
prompting an upregulation of miR-200’s (Figure 6C), did 
not completely phenocopy miR-200 expression, since 
it failed to engage a significant epithelial gene program 
(Figure 6D-6E) or upregulate CD24 in MCF10CA1h cells 
(Figure 6F).
These observations suggest that the acquisition of 
strong mammosphere growth induced by miR-200s, in 
part driven or reinforced by downregulation of ZEB2, is 
reinforced by the activation of the PI3K-Akt signaling 
pathway through indirect downregulation of PTEN. The 
Figure 5: Activation of the PI3K-Akt signaling pathway by expression of miR-200 in MCF10CA1h cells. A. 
Downregulation of known and predicted miR-200 target RNAs, determined by qPCR. As controls of miR-200 activity, the epithelial 
markers CDH1 and EPCAM are strongly upregulated, while the mesenchymal marker FN1 is downregulated. B. Induction by miR-200s 
of steady-state phosphorylation of Akt. Western blotting of total extracts of cells serum-starved for 24 h, probed with anti-pAkt (Ser473), 
total Akt or β-tubulin. C. Abrogation by LY294002 and rapamycin of miR-200(C1)-induced mammosphere growth of MCF10CA1h cells. 
D. The mTOR negative regulator TSC1 is a target of miR-200a and miR-200b, and the inositol-1,4,5-trisphosphate 5-phosphatase SYNJ1 
is a target of miR-200b. Luciferase assays were run with constructs bearing the indicated 3’-UTR fragments. E. Lentivirally-mediated 
expression of miR-200-C2 in MCF10CA1h cells induces the expression of endogenous miR-205, as determined by microarray analysis. 
F. Knockdown of PTEN induces mammosphere growth in MCF10CA1h cells. G. Knockdown of PTEN fails to enhance ALDH activity in 
MCF10CA1h cells, as assessed by the Aldefluor assay. H. Knockdown of PTEN fails to induce cell surface expression of CD24, determined 
by flow cytometry.
Oncotarget83392www.impactjournals.com/oncotarget
latter represents a novel mechanism that may explain the 
significant growth and survival advantages conferred by 
the expression of miR-200 in MCF10CA1h and, possibly, 
breast cancer cells.
After seven days of implantation in the cleared 
mammary fat pads of NOD-SCID mice, the growth 
Figure 6: ZEB2 knockdown partially phenocopies miR-200 expression in MCF10CA1h cells. A. Knockdown of ZEB2 
potentiates the mammosphere growth of MCF10CA1h cells. Top, bright field images. Bottom, MTT quantifications (n = 3). B. Knockdown 
of ZEB2 induces ALDH activity in MCF10CA1h cells. C. Knockdown of ZEB2 induces the upregulation of endogenous miR-200 family 
microRNAs, as quantified by real-time PCR. D. Knockdown of ZEB2 fails to induce MET in MCF10CA1h cells, as determined by Western 
blotting for E-cadherin and fibronectin. E. Knockdown of ZEB2 fails to upregulate cell-surface CD24 in MCF10CA1h cells. F. Knockdown 
of ZEB2 fails to induce membrane-associated E-cadherin in MCF10CA1h cells, as assessed by immunofluorescence. Phalloidin-Alexa 
Fluor 568 was used to stain cortical cytoskeleton and Hoechst 33342 for DNA staining. Size bar, 10 µm.
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of control cells stagnated while that of MCF10CA1h.
C1 cells continued at an exponential rate (Figure 7A). 
Neither control nor miR-200-expressing MCF10CA1h 
cells produced detectable metastatic growth outside of 
their sites of implantation for the duration of local growth 
monitoring and up to two additional months of follow 
up after removal of the implanted tumors. However, 
intravenous inoculation of MCF10CA1h.C1 cells resulted 
in tumor colonization of the lungs at significantly higher 
rates than control cells with a significantly higher number 
of metastases than controls (mean: 7.6 vs. 2.9 per lung) 
(Figure 7B-7C), illustrating that enhanced metastatic 
colonization and growth can be uncoupled from local 
escape functions of tumor cells [23].
miR-200s provide cues for the morphogenetic 
differentiation of MCF10CA1h cells
The induction by miR-200s of breast luminal 
progenitor properties in MCF10CA1h cells prompted us 
to interrogate whether these cells could acquire further 
differentiated features under appropriate stimuli. When 
MCF10CA1h.C1 cells were grown in 5% Matrigel 3-D 
lattices, they formed highly organized branched tubular 
structures with multiple terminal hollow alveolar-like 
structures (Figure 8A), reminiscent of the complex 
structures formed in vitro from explanted normal 
mammary epithelial progenitor cells [24]. In contrast, 
control MCF10CA1h cells only formed amorphous or 
solid spherical structures (Figure 8A). Further, by co-
expressing miR-200b and green fluorescent protein, we 
demonstrate that these cells contributed equally to both 
ductal- and alveolar-like structures (Figure 8A).
In addition to the induction of an epithelial gene 
program, expression of miR-200s in MCF10CA1h cells 
elicited a marked upregulation of the basal keratin, KRT5 
(Figure 8B-8C) and a more modest, but significant, 
induction of the luminal keratins, KRT8 and KRT18, 
as well as the basal marker, p63 (Figure 8B-8C). In 
concert with these changes, miR-200-expressing cells 
were enriched in the active transcription mark, histone 
H3K4me3, on the KRT18 promoter and depleted in the 
repressive mark, H3K27me3, on the KRT5 promoter 
(Figure 9), suggesting that the observed transcript 
modulation is at least partially attributable to a shift in 
transcriptional programs induced by miR-200s. miR200-
expressing MCF10CA1h cells also showed a significantly 
higher proliferation index than control cells as determined 
by Ki67 staining (Supplementary Figure 6). These cells 
failed to express the luminal differentiation marker, 
estrogen receptor alpha, or the myoepithelial markers, 
myosin heavy chain. Remarkably, 3-D Matrigel cultures 
of MCF10CA1h.C2 cells, and more weakly MCF10CA1h.
C1 cells, expressed the luminal differentiation master 
regulator, GATA3, which was not expressed in the absence 
of Matrigel (Supplementary Figure 6).
Tumors grown in mice upon orthotopic implantation 
of control MCF10CA1h cells displayed morphologically 
heterogeneous areas that included predominantly spindle-
shaped and mesenchymal-like elements along with areas 
that included a more epithelioid appearance that failed 
to generate glandular structures (Figure 10). In contrast, 
tumors formed by MCF10CA1h.C1 and MCF10CA1h.
Figure 7: miR-200s potentiate the tumor growth and lung colonization of MCF10C1h cells in NOD-SCID mice. 
A. Orthotopic implantation (cleared mammary fat pads) of luciferase-bearing MCF10CA1h.C1 cells, monitored by bioluminescence 
for 35 days (n = 8). B. Lung colonization assay after intravenous injection of luciferase-bearing MCF10CA1.C1 cells, monitored by 
bioluminescence for 42 days (n = 8). C. HE staining of representative tissue samples from lungs colonized by control and MCF10CA1h.
C1 cells. Size bar, 100 µm.
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Figure 8: miR-200s promote the morphogenesis and differentiation of MCF10CA1h cells. A. miR-200s promote the 
formation of pseudoalveolar (5-d culture) and complex tubuloalveolar (10-d culture) structures by MCF10CA1h cells grown in 5% Matrigel. 
The pseudoalveolar structures are hollow cavities formed by a single-cell layer as shown in 3-D reconstructions for GFP-expressing 
MCF10CA1.200b cells (right panel). Size bar, 100 µm. B. Modulation of miR-200 (Cluster1)-induced expression in MCF10CA1h cells 
of basal (KRT5, P63), luminal (KRT8, FOXA1), epithelial (CDH1, EPCAM) and self-renewal (SOX2) markers as a function of growth 
conditions (adherent, primary mammospheres, 5% Matrigel). mRNA levels were quantified by qPCR. Shown are ratios for values for 
MCFC10AC1.C1 vs control cells (fold-change). C. miR-200-Cluster 1 (left) or miR-200-Cluster 2 (right) induce an epithelial program 
(E-cadherin) and the concomitant upregulation of luminal (KRT8) and basal (KRT5) keratins in vitro (5% Matrigel 3D culture). Cells 
were formalin fixed and paraffin embedded and processed for immunostaining and diaminobenzidine-based detection with the indicated 
antibodies. Size bar, 100 µm.
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C2 cells contained fields dominated by a more epithelioid 
appearance, including areas that had undergone 
morphological differentiation into gland-like structures 
(Figure 10). Similar to the phenotypes observed in vitro, 
the epitheloid components of these tumors showed intense 
staining for E-cadherin as well as luminal (KRT8) and 
basal (KRT5) cytokeratins (Figure 10). Further, whereas 
the mesenchymal marker, vimentin, was strongly and 
diffusely expressed in control tumors, it did so only 
in spindle-cell areas of MCF10CA1h-miR200 tumors 
(Supplementary Figure 7). Although GATA3 was focally 
expressed in epithelioid areas of MCF10CA1h.C2 tumors 
(Supplementary Figure 7), all tumors failed to express 
estrogen receptor-alpha or smooth muscle myosin heavy 
chain (not shown). Finally, p63 was diffusely expressed 
in spindle-cell areas of tumors from control cells and was 
highly expressed in periglandular cells in tumors from 
MCF10CA1h-miR200 cells (Figure 10). 
To summarize, the upregulation of basal (KRT5, 
p63) and luminal (KRT8/18, GATA 3, CD24) markers by 
miR200 in these cells, together with the robust induction 
of ALDH activity and the epithelial markers, EpCAM 
and E-cadherin, as well as their capacity to undergo 
glandular differentiation upon orthotopic implantation in 
mice, reinforce the hypothesis that miR-200s drive the 
acquisition of luminal progenitor characteristics [17].
The epithelial components of metaplastic breast 
cancer express high levels of miR-200 and luminal 
progenitor cell marker profiles
The morphological features of tumors formed in 
mice by MCF10CA1h-miR200 cells are reminiscent 
of metaplastic breast cancer (MBC) with spindle cell 
component [25]. As such, we hypothesized that the 
epithelial/glandular components of human MBC would 
express high levels of miR-200 and co-express luminal 
and basal markers. Given their histological and likely 
underlying genetic and epigenetic heterogeneity of these 
rare tumors [26], we restricted this analysis to five cases 
Figure 9: Chromatin immunoprecipitation to determine enrichment of histone markers H3K4me3 or H3K27me3 ChIP 
on promoter regions of SOX2, KRT5, KRT8 or KRT18 in control or miR-200 (Cluster 2)-expressing MCF10CA1h 
cells. Shown are normalized input values for the test promoters relative to values for ACTB (H3K4me3 marks, associated with active 
transcription) or NEUROD1 (H3K27me3 marks, associated with repressed transcription).
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Figure 10: miR-200-Cluster 1 (left) or miR-200-Cluster 2 (right) induce an epithelial program (E-cadherin) and 
the concomitant upregulation of luminal (KRT8) and basal (KRT5) keratins in vivo. Immunostaining with the indicated 
antibodies of paraffin embedded tissue samples from control and miR-200 (Cluster 1 or Cluster 2)-expressing MCF10CA1h cells grown as 
orthotopic implants in cleared mammary fat pads of NOD-SCID mice.
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of the carcinosarcoma subtype, with well-delimited dual 
epithelial and mesenchymal components as determined 
by mutually exclusive expression of cytokeratins and 
vimentin. In 4 cases, we macrodissected the epithelial 
and mesenchymal components of the tumors, finding 
that the epithelial components in 3 out of the 4 tumors 
analyzed expressed significantly higher levels than the 
mesenchymal components of at least two of the five miR-
200s quantified (Figure 11A). 
Immunohistochemical analysis showed that KRT8 
was expressed in the epithelial component of all five 
carcinosarcoma MBC cases (Supplementary Table 3). 
In all but one case, the same cellular areas co-expressed 
KRT5 (Figure 11B). In addition, ALDH was also strongly 
expressed in the epithelial components of 3 of the 5 cases 
studied, corresponding to those with a strong expression 
of KRT8 and weaker or focal expression of KRT5 
(Figure 11B). As expected, E-cadherin was consistently 
and diffusely expressed in the epithelial components of 
all cases (Figure 11B) while estrogen receptor-alpha and 
HER2 were undetectable (not shown). Interestingly, one 
case with strong ALDH and KRT8 staining in the epithelial 
component also showed positive nuclear staining for 
GATA3 (Figure 11C). In sum, the epithelial components 
of MBC with double mesenchymal and epithelioid 
components (carcinosarcomas) express markers of breast 
luminal progenitor cells, including ALDH and double 
luminal-basal cytokeratins, coincident with high levels of 
miR-200s. 
DISCUSSION
In this study, we have identified sets of miRNAs 
that are dysregulated along the metastatic progression of 
IDC. Of these, only miR-200 and miR-7 showed the same 
trend in tissue samples and in blood, namely a statistically 
significant tendency for higher levels in distant metastatic 
than in node-positive primary cases and tumors (PM) and 
higher levels in PM than in node-negative primary cases 
and tumors. These concordances suggest that circulating 
miR-200 and miR-7 levels reflect the expression levels of 
these miRNAs in the tumors borne by the patients.
Previous reports have shown that miR-200s 
circulate at higher levels in association with metastasis in 
epithelial tumors [11, 27, 28] in consonance with reports 
demonstrating that circulating breast cancer cells with 
metastatic potential are predominantly epithelial [29] 
and that expression of miR-200s promotes the metastatic 
behavior of breast cancer cells [10-12]. However, a 
more broadly extended view is that miR-200s prevent 
metastasis through induction of an epithelial gene program 
in detriment of EMT and invasive properties of cells [6, 
7]. Nevertheless, in addition to shifting the balance in 
favor of epithelial gene programs, miR-200s have been 
found to negatively regulate self-renewal gene networks, 
by targeting BMI1 or SOX2 and thereby limiting the 
growth of normal and tumor cells [30]. Indeed, we have 
observed a downregulation of SOX2 upon expression of 
miR-200s. However, this was accompanied with enhanced 
mammosphere growth, suggesting that expression of 
SOX2 does not play a significant role in the self-renewal 
properties of these cells. Likewise, our observations do 
not support a role for BMI1 in the maintenance of the 
growth characteristics of these cells, and thus alternative 
mechanisms must be invoked to explain the observed 
phenotypes. In this regard, the key roles found by others 
for miR-200s and an epithelial gene program in the 
generation of induced pluripotent stem cells with high 
self-renewal characteristics [31, 32] are in agreement 
with our observations that miR-200s promote, rather 
than counter, self-renewal (mammosphere growth) and 
metastatic properties of MCF10CA1h cells. Recent reports 
also support a metastasis-promoting function of miR-200 
[10-12], in one case linked to its targeting of specific 
secretory pathways [10]. 
Our observations suggest a novel mechanism by 
which miR-200s promote self-renewal and the acquisition 
of progenitor cell characteristics, through activation of 
the PI3K-Akt-mTOR signaling pathway as a result of 
indirect downregulation of PTEN and direct targeting 
of TSC1. Although it has been reported by others that 
miR-200-family members bind to the 3’UTR of PTEN 
resulting in its downregulation [33], we have not found 
a direct interaction, which leads us to suggest an indirect 
mechanism. Relevantly, we have found that miR-205, a 
contrasted interactor and modulator of PTEN mRNA, 
is strongly upregulated in MCF10CA1h cells upon 
expression of miR-200’s. We thus propose that induction 
of miR-205 by miR-200’s through mechanisms yet 
to be determined leads to a downregulation of PTEN 
and consequent constitutive activation of the PI3K-
AKT-mTOR signaling axis. Downregulation of PTEN 
and activation of Akt and mTOR have been shown to 
be critical for proliferation and survival of CSCs and 
specifically, breast cancer stem cells [34], and an active 
PI3K/Akt/mTOR signalling axis is required for the 
maintenance of the undifferentiated properties of ESCs 
[35] and iPS cells [36]. Interestingly, the acquisition of 
a CSC-like phenotype by reprogramming differentiated 
luminal-like cells is associated with the activation of 
mTOR [37].
A further relevant and novel finding of our study 
is the induction by miR-200s of luminal progenitor-like 
features in MCF10CA1h cells, endowing them with a 
capacity for morphological differentiation, accompanied 
with the expression of markers associated with that stage 
in the differentiation of mammary epithelial cells. Thus, 
under the influence of miR-200’s, MCF10CA1h cells 
develop well-defined albeit imperfect (monolayered 
rather than bilayered) tubuloalveolar structures and engage 
limited proneness to display luminal differentiation, with 
weak expression of GATA3 when grown in Matrigel or 
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Figure 11: The epithelial components of metaplastic breast cancer can express high levels of miR-200s and markers 
of luminal progenitor cells. A. Expression levels of miR-200a, miR-200b, miR-200c and miR-429 in enriched epithelial components 
relative to mesenchymal components of MBC samples, determined by qPCR. B. The epithelial components of MBC samples can co-express 
E-cadherin, KRT8, KRT5 and ALDH, determined by immunohistochemical analysis. Samples labeled 1-4 correspond to the samples with 
the same labels in (A). Size bar, 100 µm. C. Immunostaining of a metaplastic breast cancer case displaying weak but clear nuclear staining 
for GATA3. Size bar, 100 µm.
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in vivo but failure to express estrogen receptor. These 
observations suggest that complex breast morphogenetic 
events can take place in the absence of terminal 
differentiation of the two major breast epithelial lineages, 
that miR-200s promote this process and that environmental 
factors, yet to be identified, provide additional cues that 
drive the differentiation of miR-200-expressing breast 
epithelial cells along the luminal lineage. 
The induction of high levels of ALDH activity, a 
CD44highCD24high haplotype, enhanced mammosphere 
growth, alveolotubular morphogenesis in vitro and in 
vivo, and a proneness to luminal differentiation support 
our proposal that miR-200s induce a luminal progenitor 
phenotype in MCF10CA1h cells. In the context of our 
observations, prior evidences that constitutive expression 
of miR-200 in breast stem cells causes attrition of luminal 
progenitor cells thus preventing luminal differentiation 
and correct breast morphogenesis [30] may indicate 
that the promotion by miR-200s of luminal progenitor 
phenotypes occur within defined developmental windows 
and that prolonged expression cripples normal progenitor 
cells in physiological contexts. Our observation of high 
levels of expression of miR-200s in breast cancer cells 
with aggressive phenotypes or in MCF10CA1a cells 
indicate that the compromise in viability imposed by 
constitutive expression of miR-200s in normal breast stem 
cells can be overcome by factors that drive spontaneous 
(neoplastic) or experimentally induced immortalization. 
The precise correspondence of the MCF10CA1h cell line 
to a physiological stage along the mammary epithelial 
lineage has not been established, and therefore it is 
difficult to propose whether miR-200s drive these cells 
from a less differentiated to a more differentiated stage 
or in the converse direction. The failure of these cells 
to undergo full terminal differentiation after miR-200s 
expression is more likely related to specific constraints 
pertaining to MCF10 cells, either inherent in the original 
cells or acquired through the generation of different 
immortalized variants and subpopulations [14, 15] than to 
a differentiation block imposed by miR-200s [30].
Our analysis of metaplastic breast cancer samples 
indicates that tumor cells expressing epithelial programs 
and miR-200s can co-express luminal and basal keratins 
and ALDH. Co-expression of luminal and basal keratins 
in MBC has been reported previously and interpreted 
as a reflection of the cells of origin of these tumor cells 
being bipotent stem cells or myoepithelial cells [38-
40]. Although such interpretations may apply to some 
subtypes of MBC, they may not suit the carcinosarcoma-
type cases, since they fail to consider that normal breast 
epithelial stem cells express low levels of ALDH [18] and 
that myoepithelial cells do not express luminal keratins 
[17]. In light of the evidences presented herein for the 
MCF10CA1h cell model, our findings of co-expression 
of luminal and basal keratins and ALDH suggests that 
the epithelial neoplastic components of a subset of 
MBC may have originated in cells expressing an early 
progenitor luminal phenotype but retaining bipotent 
features. Evidences suggest that most other types of breast 
cancer originate from luminal progenitor cells [17, 41], 
with a minority of tumor types, including claudin-low 
and some metaplastic tumors [26], possibly originating 
from less differentiated cells that might correspond to 
mammary stem cells [17]. The epithelial components of 
MBC may harbor sufficient phenotypic plasticity to give 
rise to mesenchymal (and other metaplastic) neoplastic 
components through the engagement of EMT in response 
to epigenetic cues or genetic mutations [42, 43]. In 
addition, based on our observations with MCF10CA1h 
cells, we propose that the more intrinsically aggressive 
components of MBC are the epithelial components, 
rather than the mesenchymal components. Indeed, 
metastatic samples from MBC tend to display hallmarks 
of epithelial differentiation [44] and subtypes with a 
higher representation of epithelial components have 
been reported as associated with higher rates of distant 
metastasis and worse outcomes than those with a greater 
representation of mesenchymal components [45]. 
In conclusion, we propose that microRNAs of the 
miR-200 family promote traits of highly proliferative 
breast luminal progenitor cells and may contribute 
to exacerbate the growth and metastatic properties of 
transformed breast epithelial cells, including those present 
in histological variants such as metaplastic carcinomas.
Supporting Information is available online, 
containing Supplementary Tables and Figures
MATERIALS AND METHODS
Sample procurement and processing
All patient samples were procured through the 
Hospital Clínic-IDIBAPS Biobank. Formalin-fixed 
and paraffin-embedded (FFPE) samples from invasive 
ductal carcinomas were selected on the basis of estrogen 
receptor (ER), progesterone receptor (PR) and HER2 
expression. Also, normal breast epithelial tissues from 
patients undergoing reductive mammoplasty were 
collected (Supplementary Table 1). Samples with > 70% 
tumor epithelial enrichment were macrodissected to 
minimize stromal and lymphocytic components. Blood 
samples were collected from untreated breast cancer 
patients at diagnosis and 6 healthy women with negative 
mammographies (Supplementary Table 2).
Immunohistochemical analyses
Tissue microarrays (TMA) were built from paraffin-
embedded samples bearing 3-µm thick, 1-mm diameter 
triplicate cores. Samples included those used in the 
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initial microRNA screening and subsequent analyses, 
and additional infiltrating carcinomas and lymph node 
metastases as well as 5 metaplastic breast carcinomas of 
the carcinosarcoma type. Samples were deparaffinized and 
rehydrated (PTLink module, Dako Omnis) prior to antigen 
retrieval (97 ºC for 20 min with the EnVision™ FLEX 
low and high pH Target Retrieval Solutions, Dako Omnis, 
or 95º for 30 min with the Cell Conditioning Solution, 
Ventana), followed by incubation with primary antibodies 
(Supplementary Table 4), incubation with polymer-
peroxidase-conjugated secondary antibody and developed 
with diaminobenzidine. Slides were counterstained with 
haematoxylin, dehydrated and coverslipped. The reaction 
specificity was ascertained by the absence of staining when 
using a non-specific isotype-matched primary antibody. 
Nuclear immunostaining for ERα, PR and GATA3 
was scored according to intensity (I; 0, 1, 2 and 3) and 
percentages of positive cells. Hscores ≥ 2 were considered 
as positive staining. Membrane staining for HER2 was 
assessed as 0, 1, 2 and 3, following recommendations of 
the American College of Pathologists [46]. Only cases 
with HER2 score equal to 3 were considered HER2(+). 
Primary tumors were classified according to the expression 
of hormone receptors and HER2. Cases were considered 
as “luminal” with positive ER and/or PR (≥ 10% positive 
cells) and negative HER2 (0, 1). Membrane E-cadherin 
expression was scored according to the product between 
the intensity coefficient (0, negative; 1, low; 2, moderate; 
3, strong) and the frequency of positivity coefficient (0, no 
stained cells; 1, 1-9%; 2, 10-49%; 3, 50-79%; 4, 80-100%) 
and classified as follows: 0, negative score; 1+, score 1-4; 
2+, score 5-8; 3+, score 9-12 [47].
RNA isolation, reverse transcription and real-time 
RT-PCR of cell culture samples
For RNA extraction of adherent cells, cells were 
grown to 70-80% confluence and lysed directly on the 
plate with Qyazol lysis reagent. Mammospheres were 
collected by gentle centrifugation and resuspended with 
Qyazol. 3D structures were recovered from Matrigel 
using the non-enzymatic solution Matrisperse (Cultek), 
following manufacturer’s instructions, and resuspended in 
Qyazol after gentle centrifugation. RNA was isolated with 
the miRNeasy Mini kit (Qiagen). cDNA was synthesized 
with the HighCapacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Real-time quantitative PCR assays 
were performed on a LightCycler 480 instrument (Roche) 
and analyzed with the LightCycler 480 Software release 
1.5.0. The Universal Probe Library system (UPL) (Roche) 
was used to quantify transcripts. Probes and sequences are 
shown in Supplementary Table S5. RN18S5 amplification 
levels were used as an internal reference, and relative 
transcript quantification determined by the ∆∆Cp method.
MicroRNA microarray analysis
Total RNA was extracted from FFPE tissues with 
the miRNeasy FFPE kit (Qiagen), labeled using the 
Agilent miRNA Labeling and Hybridization Kit (Agilent 
Technologies Incorporated, Santa Clara CA, USA), 
hybridized to Agilent Human miRNA microarrays (V12.0, 
Agilent), scanned on an Agilent scanner and feature 
extracted using Agilent Feature Extraction Software 
(version 10.5.1.1). Quantile normalization was performed 
using the “normalize.quantiles” function from the “affy” 
R package in Bioconductor (http://www.bioconductor.org) 
and invariant and highly expressed microRNAs selected 
[48]. Raw data for this analysis are accessible at Gene 
Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/ 
(GSE86995).
MicroRNA quantitative PCR
Total RNA was retrotranscribed with the Universal 
cDNA Synthesis kit (Exiqon). Mature microRNAs were 
detected using the ExiLENT SYBR Green Master Mix 
(Exiqon) and specific LNA™ primers. miR-16 and let7a 
were used as reference microRNAs. Real-time quantitative 
PCR assays were performed on a StepOnePlus instrument 
(Life Technologies). Relative quantifications were 
assessed by the ∆∆Cp method. Normalized values were 
used in comparative analysis between categories of 
samples using either parametric (t-test) or non-parametric 
tests (Mann-Whitney). For quantification of miR in blood, 
total RNA was isolated from 2.5 mL of blood collected in 
PAXgene Blood RNA tubes (Qiagen), retrotranscribed and 
microRNA levels determined by real-time PCR as above, 
using miR-16 and miR-103a-3p as references.
mRNA microarray analysis
Total mRNA was isolated and processed for 
hybridization on Human Gene ST 2.1 strips (Affymetrix). 
Signals were fitted with a probe-level model and 
expression values were calculated and log
2
 transformed 
using a robust multi-array average (RMA) [49]. Probes 
with ≥ 2-fold change in intergroup comparisons were 
selected for hierarchical clustering analysis and heatmap 
plotting [50].
Cell culture
MCF10CA1a and medium MCF10CA1h cells were 
maintained in DMEM/F12 supplemented with 5% horse 
serum, 10 μg/mL insulin (Sigma-Aldrich), 20 ng/mL 
epidermal growth factor (Life Technologies), 0.5 μg/mL 
hydrocortisone (Sigma-Aldrich), and 50 ng/mL cholera 
toxin (Sigma-Aldrich).  The human breast carcinoma cell 
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lines MDA-MB-468 and MCF7, the MDA-MB-231 cell 
derivatives SCP2 and SCP6 and HEK293T cells were 
cultured in DMEM culture medium (PAA) containing 10% 
fetal bovine serum and penicillin/streptomycin. Cells were 
grown at 37 °C in a 5% CO2 atmosphere.
Collagen I 3-D culture
Type I collagen was isolated from mouse tail 
tendons as described previously [51] and dissolved in 
0.2% acetic acid at a final concentration of 2.7 mg/mL 
Before gelation, the collagen solution was mixed with 10× 
minimum essential media (MEM) and 0.34 N NaOH at 
a ratio of 8:1:1 at 4 °C, with MCF10CA1h control and 
MCF10CA1h. C2 cells (1-5 × 106) suspended in 1 mL of 
this mixture. The carcinoma cell-collagen mixtures were 
incubated for 1 h at 37 °C to allow for gelation and culture 
media (MEM supplemented with 10% FCS) added atop 
the gel.
Wound-healing assay
Cells were seeded in 24-well plates (Corning) at 2 
x 104/well in DMEM:HAM medium supplemented with 
5% horse serum (HS). After reaching 80% confluence, 
the medium was replaced with fresh medium devoid of 
serum containing 0.5% (w/v) mitomycin C (Sigma). 
After 1 h of treatment, medium was replaced with fresh 
medium supplemented with 0.5% HS and approximately 
1-mm wide wounds produced in the confluent monolayer. 
Wounds were imaged at 0 h, 12 h, 24 h and 48 h and 
analyzed with the aid of Image J. At least three wounds 
per condition were scored.
In vitro invasiveness assay
Transwell chambers (Costar) with 8-µm diameter 
pore membranes were coated with growth factor-
reduced Matrigel (BD Biosciences) at 410 µg/mL. Cells 
were serum-deprived for 24 h, detached, resuspended 
in medium supplemented with 1% BSA/0.5% FBS and 
then seeded (1.5 x 105/well in 24-well plates) onto the 
pre-coated Transwell inserts, with the lower chamber 
containing medium supplemented with 0.5% FBS. After 
24 hours, cells migrating to the lower chamber were 
collected by detachment with trypsin-EDTA, washed 
with PBS, and fluorescent cells scored in a Coulter Epics 
XL instrument (Coulter Electronics, Luton, UK). Each 
condition was done in quadruplicate.
Cytotoxicity assay
Cells were seeded in 96-well plates (Corning) 
at 1.5 x 103 cells/well, allowed to attach overnight and 
exposed to varying concentrations of drugs for 96 h. After 
treatment, 10 µL of MTT ((3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) solution (Sigma) 
were added and incubated at 37 °C for 3 h. Crystals were 
solubilized with 100 µL of 0.08 M HCl/isopropanol by 
shaking for 30 min in the dark, and absorbance recorded at 
570 nm. Each condition was done in quintuplicate.
Mammosphere growth
MCF10 variant cell lines were obtained from the 
Karmanos Cancer Institute (MTA with Y. Kang). Cells 
were grown in DMEM:F12 medium supplemented with 
B27, 20 ng/mL EGF, 20 ng/mL bFGF (Life Technologies), 
4 μg/mL heparin, 5 μg/mL insulin and 0.5 mg/mL 
hydrocortisone (Sigma-Aldrich). Cells (104/mL) were 
plated per well 24-well in ultralow attachment plates 
(Corning). For serial passages, mammospheres were 
centrifuged at 800 rpm, dissociated with 0.05% trypsin, 
0.53 mM EDTA, sieved through a 70-μm sieve, analyzed 
microscopically for single-cellularity and replated. 
Colonies were stained with MTT, images acquired and 
areas quantified with Image J.
Differentiation culture conditions
3D cultures were performed as previously described 
[52]. Primary mammospheres were dissociated and 
grown in DMEM:Ham’s F-12 medium with 5% Matrigel 
(Corning), 5% 24-well, 10 μg/mL insulin, 0.5 μg/mL 
hydrocortisone, 10 μg/mL cholera toxin, 10 ng/mL EGF, 
and 1× Pen/Strep. Single cell suspensions were plated on 
Matrigel-precoated plates at a density of 40,000 cells/mL 
and allowed to form three-dimensional structures for 10-
14 days.
Lentiviral production and transduction
For the generation of stable miR-200 overexpressing 
cell lines, pMSCV-puro with our without the 
genomic fragment harboring miR-200 cluster 1 (miR-
200a/200b/429), pMSCV-hygro with our without the 
genomic fragment harboring cluster 2 (miR-200c/141), 
were co-transfected with pVSVG into the retrovirus 
packaging cell line PG13 (Clontech, Mountain View, 
CA, USA) using X-tremeGENE9 (Roche). Supernatants 
were collected for the following 48 h and filtered through 
0.45 μm methylcellulose filters (Millipore). Virus-
containing supernatants were used to infect target cells 
in the presence of polybrene (8 μg/mL; Sigma-Aldrich), 
and selected with 1 μg/mL puromycin (Sigma-Aldrich) 
or 50 μg/mL hygromicin B for 7 days. To overexpress 
hsa-miR-200b, the pCDH-CMV-MI0000342-EF1-
copGFP lentiviral vector and its control were purchased 
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from System Biosceinces (Paolo Alto, CA, USA). Each 
plasmid was co-transfected in HEK293T cells with 
pVSVG and pCMVΔR8.91 (Clontech, Mountain View, 
CA) using X-tremeGENE9 (Roche). Supernatants were 
collected for the following 48 h, filtered through 0.45 
μm methylcellulose filters (Millipore) and were used 
to infectthe target cells in the presence of polybrene (8 
μg/mL; Sigma-Aldrich). At 72 hours after infection, 
successful gene transfer was confirmed by visualization of 
GFP by fluorescence microscopy and positive cells were 
enriched by fluorescence-activated cell sorting (FACS) 
(MoFlo, Beckman Coulter).
For the generation of stable ZEB2 and PTEN 
knockdown cell lines, after screening for the most effective 
specific knock down shRNAs (5 distinct target sequences 
per mRNA), pLKO.1-Puro plasmids for control (shC002), 
ZEB2- or PTEN-targeting shRNAs (TRCN0000013528 
and TRCN0000002745, respectively) (Sigma-Aldrich) 
were co-transfected in HEK293T cells with pVSVG and 
pCMVΔR8.91 (Clontech, Mountain View, CA, USA) 
using X-tremeGENE9 (Roche). Supernatants were 
collected for the following 48 h and filtered through 
0.45 μm methylcellulose filters (Millipore. Target cells 
were transduced with the supernatans in the presence of 
polybrene (8 μg/mL; Sigma-Aldrich), and selected with 1 
μg/mL puromycin (Sigma-Aldrich) for 5 days.
Flow cytometry
Aldehyde dehydrogenase activity was detected 
with the Aldefluor kit (Stem Cell Technologies) used 
according to manufacturer’s protocol and analyzed by 
flow cytometry on a Gallios Flow Cytometer instrument 
(Beckman Coulter). For cell surface immunophenotyping, 
cells were detached with 0.25% trypsin/ 0.1% EDTA, 
washed and incubated with primary antibodies CD44 
(Alexa Fluor 647, anti-mouse/human, 1:4000 dilution, 
BioLegend) and CD24 (Alexa Fluor 488, anti-human, 1:20 
dilution, BioLegend) in PBS/3% normal goat serum for 
30 min in a shaker at 4 °C, washed and analyzed by flow 
cytometry.
Western blotting
Samples were resuspended in Laemmli buffer 
(100 mM dithiothreitol, 50 mM TrisCl pH 6.8, 2% SDS, 
0.1% bromophenol blue, 10% glycerol) and boiled for 5 
min. Equal amounts of protein were resolved by SDS-
PAGE. After electrophoresis, proteins were transferred 
onto fluorescent-PVDF membranes (Immobilon-FL, 
Millipore) for 2-4 h. Blots were washed, blocked with 
blocking buffer (Odyssey, LI-COR Biosciences, Lincoln, 
NE, USA), incubated overnight with primary antibody 
diluted in blocking buffer-PBS (or TBS)-Tween (0.1%) 
(1:1), washed in PBS-T (or TBS-T) and incubated for 1 
h with IRDye fluorescent secondary antibody (LI-COR). 
After final washes in PBS-T (or TBS-T), the membranes 
were scanned using the Odyssey Infrared Imaging System 
(LI-COR). Antibodies to the following antigens were 
used: E-cadherin (1:8000) (BD Bioscience), FN1 (1:2000) 
(Sigma), N-cadherin (1:1000) (BD Bioscience), Vimentin 
(clone V9, 1:2000) (Labvision) and β-tubulin (1:2000) 
(Sigma).
3’UTR luciferase reporter assays
psiCHECK2-PTEN 3’UTR construct was obtained 
from Addgene (Plasmid 50936). A plasmid containing 
the 3’UTR of SYNJ1 was generated by cloning a 3’UTR 
fragment of 628 bp using the Zero Blunt PCR cloning kit 
(Invitrogen). Due to size constraints, TSC1 3’UTR was 
cloned as three different fragments (Fragment #1:483bp; 
fragment #2: 941bp; fragment #3: 368bp) into the pCR 
Blunt vector. SYNJ1 and TSC1 3’UTR fragments were 
subcloned into psiCHECK-2 (Promega) using XhoI 
and NotI restriction sites. The primers used are listed in 
Supplementary Table S6. Reporter assays were performed 
as follows: HEK293T were transduced with lentiviral 
particles carrying either pmiR-empty or pmiR-200b. 
Seventy-two hours post-infection, cells were seeded into 
96-well plates and transfected with 50 ng of the indicated 
3’UTR reporter vectors for an additional 24 h (n = 4 per 
condition). Luciferase activity was measured using the 
Dual-Glo Luciferase AssaySystem (Promega). Renilla 
luciferase activity was normalized to corresponding 
firefly luciferase activity and plotted as a percentage of 
the control.
Chromatin immunoprecipitation
Adherent cells were fixed in 1% formaldehyde 
for 10 min, quenched with 0.125 M fresh glycine for 5 
min, washed twice with PBS, lysed (1% SDS; 10 mM 
EDTA pH8.0; 50 mM Tris-HCl pH 8.1, with protease 
inhibitors), and samples were kept on ice for 20 min. 
Cell lysates were sonicated in a Branson 450 sonicator 
(5 cycles of 20 seconds at 30% amplitude) to yield 200-
500 bps chromatin fragments. Chromatin was purified 
by centrifugation at 13,200 rpm at 4 ºC for 30 min, 
precleared with protein A agarose during 30 min and 25 
µg of chromatin were immunoprecipitated with 5 µg of 
one the following antibodies: H3K27me3 (Millipore 07-
449), H3K4me3 (Abcam ab8580) or nonspecific rabbit 
IgGs (Diagenode C15410206). Antibody-chromatin 
complexes were recovered with magnetic beads (Magna 
ChIP™ Protein A Magnetic Beads (Millipore 16-661) 
and immunocomplexes were washed once with TSE I 
(0.1% SDS; 1% Triton-X100; 2 mM EDTA pH 8.0; 20 
mM Tris-HCl pH 8.1; 150 mM NaCl), TSE II (0.1% 
SDS; 1% Triton-X100; 2 mM EDTA pH 8.0; 20 mM Tris-
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HCl pH 8.1; 500 mM NaCl), TSE III (0.25 M LiCl; 1% 
NP-40; 1% Sodium Deoxicholate; 1 mM EDTA pH8.0; 
10 mM Tris-HCl pH 8.1) and twice with TE (10 mM 
Tris-HCl, 1 mM EDTA). Crosslinking was reversed by 
overnight incubation at 65 ºC in elution buffer (1% SDS, 
0.1 M NaHCO
3
). DNA was purified by phenol-chloroform 
extraction followed by ethanol precipitation. Enrichment 
of target regions was determined by qPCR in a Lightcycler 
480 instrument (Roche) using the primers listed in 
Supplementary Table S7. A fraction of input was used 
for the quantification of the immunoprecipitated material 
with respect to the total starting chromatin and the latter 
values for nonspecific IgG subtracted from values for 
specific antibodies. A region in the ACTB promoter was 
used as a control for the enrichment of H3K4me3 marks, 
and a region in the NEUROD1 promoter as a control for 
the enrichment of H3K27me3 marks. Percent input values 
for test promoter regions were normalized against these 
two controls to calculate relative enrichments in these two 
histone marks.
In vivo tumorigenic and lung colonization assays
Cells were transduced with pCMV-GFP/luc for the 
constitutive co-expression of the firefly luciferase gene 
and GFP and selected by FACS. Female SCID-NOD mice 
(8-10 weeks) were injected with 50 µL of 2 x 106 cells 
suspended in 50% Matrigel/PBS into cleared abdominal 
mammary fat pads. Tumor growth was monitored after 
intraperitoneal injection of 150 mg/kg D-luciferin (Caliper 
Life Science) and imaging in an ORCA-2BT instrument 
(Hamamatsu Photonics). To assess lung colonization, 5 x 
105 cells in 150 µL were injected in the tail vein of mice.
Study approval
All protocols involving patient selection and sample 
procurement complied with Spanish laws regarding 
data protection and written informed consent and were 
approved by the Hospital Clinic - IDIBAPS Ethics 
Committee and Review Board. All animal procedures 
were reviewed and approved by the Institutional Animal 
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